Cosmo First Ltd

- No major new capex or expansion plans are currently planned, indicating no immediate need for large fundraising. - The company’s recent strategic capex of ₹1,140 Cr is largely complete, shifting focus to full capacity utilization and specialty business growth. - The management emphasized a clear roadmap to substantially reduce net debt over the next 2-3 years by using free cash flow, aiming to cut around ₹200-250 Cr annually from the current net debt of approximately ₹1,200 Cr. - Weighted average cost of debt is competitive at 6.5%-6.8%, with some benefits yet to fully kick in from the recent reduction in interest rates. - The focus on reducing net debt and no mention of fresh capital raising suggest no near-term plans for raising funds through debt or equity.

- No major capex plans currently; the capex cycle is largely complete after strategic investments of over ₹1,140 Cr. - Focus going forward is on fully utilizing existing capacities and growing the specialty business. - Company aims to sweat the recent strategic capex and reach full capacity utilization across new lines (BOPP, BOPET, CPP). - Future capital allocation will be based on incremental ROCE and the value added to intrinsic business value. - No significant new capex or major BOPP assets will be added over the next three years. - Emphasis on shifting business mix towards high-margin specialty and semi-specialty products. - Business verticals like specialty chemicals and consumer businesses are scaling and expected to contribute to incremental ROCE without large capital outlays. - Strategic demerger planned for Zigly pet care business in FY27, but this is a structural move, not a capex.

- The company expects double-digit revenue growth in coming quarters driven by enhanced utilization of recently added capacity. - Specialty business to grow at a 10% CAGR, with targets to increase specialty and semi-specialty share from 57% (Q3 FY26) to about 65% by 2027-28 and 70% in a couple of years thereafter. - Consumer businesses like Zigly (pet care) are scaling up with over 50% topline growth in Q3 FY26. - U.S. business (~₹400 Cr currently) expected to grow aggressively post-tariff reduction, with growth targets higher than low double digits. - Export markets including U.S., Europe, Korea, and Japan indicate good growth potential, with Korea and Europe expected to yield results within 12 months; Japan is slower but promising long-term. - Full capacity utilization expected for new BOPP and BOPET lines by FY27; CPP line expected to reach full utilization over a longer horizon. - No major capex planned; focus on maximizing returns from existing assets.

- Double-digit revenue growth expected in coming quarters due to enhanced utilization of recently added capacity (Page 3). - Margin improvement of close to ₹50 crores anticipated for full next year, coupled with growth in revenue and incremental margins (Page 11). - Specialty business projected to grow at 10% CAGR, with plans to increase specialty and semi-specialty mix from 55% currently to 65% by FY27-28 and 70% within a couple of years (Pages 12, 13). - Margin recovery expected with USA tariff reduction benefiting profitability starting Q1 FY27 (Pages 3, 10, 11). - Full capacity utilization targeted for BOPP and BOPET lines, with CPP line expected to take 12 more months to reach full utilization, contributing to margin and earnings growth (Pages 6, 10). - No major capex planned, focus on sweating existing ₹1,140 crore capex to drive intrinsic value growth and return on capital employed (Page 15). - Net debt reduction by ₹200-250 crores yearly, strengthening financial resilience and supporting earnings stability (Page 8, 15).

The transcript does not explicitly mention specific details about the current or expected order book or pending orders. However, some relevant points related to orders and capacity utilization are: - The new BOPP line operated at around 70-80% of potential capacity in Q3 and is expected to reach full utilization (100%) from March onwards. - Demand in Q3 was range-bound, with expectations of improvement in Q4 and Q1. - Specialty business is expected to grow by around 10% CAGR, supported by the new capacities. - Export markets like the US, Europe, and Korea expected to drive aggressive growth, especially post FTAs and tariff reductions. - Some growth in the US market was curtailed earlier due to tariffs, but customer engagement is improving, signaling recovering order momentum. - The company aims to fully utilize commissioned capacities with no major capex planned in the near term. No explicit quantified orderbook or pending order values were disclosed.